Skip to main content

GRAIL, Inc.

corporate_fare Company Profile

GRAIL, Inc.

GRAL·NASDAQ·Industrial Applications And Services·CIK 0001699031

Our Company is a commercial-stage healthcare company focused on early cancer detection at population scale. The company's mission is to detect cancer early, when it can be cured. Its multi-cancer early detection test, "Galleri," screens for many types of cancer from a simple blood draw. Galleri accurately predicts the specific organ or tissue type where the cancer signal originated (the "Cancer Signal of Origin," or "CSO"), with high positive predictive values ("PPV") and low false positive rates. Galleri has detected aggressive cancers in early stages, including endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers. The company has conducted a clinical program with data from over 385,000 participants. Over 800,000 tests have been processed across this clinical program and from commercial experience, including through partnerships with healthcare systems, employers, digital health platforms, payors, and life insurance providers. The company announced results from two large clinical trials, PATHFINDER 2 and NHS-Galleri Trial, and included certain results in its pre-market approval application ("PMA") to the Food and Drug Administration ("FDA"), with the last module submitted in January 2026. Performance and safety data from the first approximately 25,000 participants of the approximately 35,000 participant PATHFINDER 2 study were presented in October 2025. These "PATHFINDER 2 Initial Results" showed that adding Galleri to recommended screenings (breast, cervical, colorectal, and lung) led to a cancer detection rate more than a seven-fold increase in cancers found within a year, and an approximately three-fold increase when prostate screening was included.

GRAIL, Inc. (NASDAQ:GRAL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for GRAL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for GRAL spans 10-Q, 144, 8-K, DEF 14A.

Recent high-impact activity:

  • GRAIL Q3: Galleri Revenue Up 14% to $37.3M, Net Loss Widens to $103.6M
  • Galleri Revenue Up 14% but Net Loss Widens to $103.6M; FDA Decision Due Early Q1 2027
  • FDA Panel Backs GRAIL's Galleri Cancer Test, Clearing Key Hurdle
  • Grail Trading Halted Ahead of FDA AdCom on Galleri Blood Test
  • GRAIL CEO Joshua Ofman Files to Sell 71,452 Shares Worth $5.77M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$147.17M
Net Income
-$408.35M
Diluted EPS
-$11.11
Op. Cash Flow
-$299.01M
Free Cash Flow
-$299.92M
Operating Income
-$562.16M
Cash & Equivalents
$249.73M
Debt / Equity
0.00×
Net Margin
-277.5%
Shares Outstanding
36.75M sh
Source: 10-K · filed 2026-03-12 · accession 0001628280-26-017319

Short Interest & Short Volume

8.70 days to cover

FINRA reported short interest of 7,998,817 shares in GRAL as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 74.3% of GRAL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,998,817 shares as of October 30, 2026
Change vs prior period▼ 2.1%
Days to cover8.70 at avg daily volume of 919,782
Daily short volume (FINRA facilities)74.3% of 278,429 shares on November 20, 2026
5-day average short volume67.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with G →
$103.49 +4.27% today
52-week range · as of 2026-11-05 $41.5 – $166.47
Market cap
$4.46B
Volume
758K (0.9× avg)
3-mo avg 854.9K
Live data · 2026-11-21 22:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GRAL - Latest Insights

GRAL
Nov 05, 2026, 4:09 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $119.13
Real-time Price: $103.49 info
Change: -$15.64 (-13%) info
Market Cap: $4.462B info
GRAL
Nov 04, 2026, 4:02 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $135.67
Real-time Price: $103.49 info
Change: -$32.18 (-24%) info
Market Cap: $4.462B info
GRAL
Sep 23, 2026, 6:17 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $108.52
Real-time Price: $103.49 info
Change: -$5.03 (-5%) info
Market Cap: $4.462B info
GRAL
Sep 23, 2026, 8:07 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $109.91
Real-time Price: $103.49 info
Change: -$6.42 (-6%) info
Market Cap: $4.462B info
GRAL
Sep 21, 2026, 4:34 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $107.97
Real-time Price: $103.49 info
Change: -$4.48 (-4%) info
Market Cap: $4.462B info
GRAL
Sep 21, 2026, 12:37 PM EDT
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $107.76
Real-time Price: $103.49 info
Change: -$4.27 (-4%) info
Market Cap: $4.462B info
GRAL
Aug 06, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $64.97
Real-time Price: $103.49 info
Change: +$38.52 (+59%) info
Market Cap: $4.462B info
GRAL
Aug 05, 2026, 4:02 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $68.00
Real-time Price: $103.49 info
Change: +$35.49 (+52%) info
Market Cap: $4.462B info
GRAL
Jul 14, 2026, 6:17 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $71.80
Real-time Price: $103.49 info
Change: +$31.69 (+44%) info
Market Cap: $4.462B info
GRAL
Jun 29, 2026, 3:31 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $68.50
Real-time Price: $103.49 info
Change: +$34.99 (+51%) info
Market Cap: $4.462B info
GRAL
May 30, 2026, 8:14 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $73.00
Real-time Price: $103.49 info
Change: +$30.49 (+42%) info
Market Cap: $4.462B info
GRAL
May 07, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $61.72
Real-time Price: $103.49 info
Change: +$41.77 (+68%) info
Market Cap: $4.462B info
GRAL
May 05, 2026, 4:22 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $53.00
Real-time Price: $103.49 info
Change: +$50.49 (+95%) info
Market Cap: $4.462B info
GRAL
May 05, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $53.80
Real-time Price: $103.49 info
Change: +$49.69 (+92%) info
Market Cap: $4.462B info
GRAL
Apr 28, 2026, 4:18 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $52.52
Real-time Price: $103.49 info
Change: +$50.97 (+97%) info
Market Cap: $4.462B info
GRAL
Mar 12, 2026, 4:45 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $43.48
Real-time Price: $103.49 info
Change: +$60.01 (+138%) info
Market Cap: $4.462B info
GRAL
Mar 12, 2026, 4:40 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $44.50
Real-time Price: $103.49 info
Change: +$58.99 (+133%) info
Market Cap: $4.462B info
GRAL
Feb 19, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $69.58
Real-time Price: $103.49 info
Change: +$33.91 (+49%) info
Market Cap: $4.462B info
GRAL
Jan 12, 2026, 10:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $97.86
Real-time Price: $103.49 info
Change: +$5.63 (+6%) info
Market Cap: $4.462B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets